Page last updated: 2024-12-07

at 2153

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

probimane: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125610
SCHEMBL ID9035259
MeSH IDM0155667

Synonyms (27)

Synonym
95604-83-4
at-2153
probimane
mst-02
2,6-piperazinedione, 4,4'-propylidenebis(1-(morpholinomethyl)-, (+-)-
mm 159
(+-)-4,4'-propylidenebis(1-(morpholinomethyl)-2,6-piperazinedione)
dl-1,2-bis(4-morpholinomethyl-3,5-dioxopiperazin-1-yl)propane
1-(morpholin-4-ylmethyl)-4-[2-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]propyl]piperazine-2,6-dione
at 2153
108093-90-9
bis(4-morpholinomethyl-3,5-dioxopiperazin-1-yl)propane
2,6-piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis(1-(4-morpholinylmethyl)-
SCHEMBL9035259
4,4'-(propane-1,2-diyl)bis(1-(morpholinomethyl)piperazine-2,6-dione)
DTXSID70910622
4,4'-(propane-1,2-diyl)bis{1-[(morpholin-4-yl)methyl]piperazine-2,6-dione}
at2153
dl-1,2-bis(4-morpholinomethyl-3,5-dioxopiperazin-1-yl)-propane
MAUYWACILHVRLR-UHFFFAOYSA-N
AKOS032960461
EX-A2489
4,4'-(1-methyl-1,2-ethanediyl)bis(1-(4-morpholinylmethyl)-2,6-piperazinedione)
mm-159
1-(morpholin-4-ylmethyl)-4-[1-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]propyl]piperazine-2,6-dione
BCP18393
at 2153;at2153;probimane

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"After determining the lethal dosage of Pro and Raz, we assessed and compared the inhibitory effects of Pro and Raz against primary tumor growth and metastatic occurrences of LLC at the dosage of LD5."( Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo.
Ding, J; Lu, DY; Xu, B, 2004
)
0.32
" In animal experiments, Pro and Raz were active against primary tumor growth (35-50 %) and significantly inhibited pulmonary metastasis of LLC (inhibition > 90 %) at dosage below LD(5)."( Medicinal chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines.
Ding, J; Huang, M; Lu, DY; Xu, B; Xu, CH; Zhu, H, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's4 (30.77)18.2507
2000's3 (23.08)29.6817
2010's2 (15.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.76 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]